Sevoflurane's Effect on Neurocognition Study

NCT ID: NCT06044740

Last Updated: 2025-12-18

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-17
• Study Completion Date: 2026-03-01

Brief Summary

The purpose of this study is to determine the effects of acute pain on long-term memory and conditioned physiologic responses in the presence and absence of low dose sevoflurane. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena. The study will occur over 2 visits and involves no long-term follow up.

Detailed Description

This is a non-randomized, clinical trial study of healthy volunteer subjects, which will employ neuroimaging and behavioral measures to characterize the effects of inhalational sevoflurane on pain processing and cognitive function. Sedative doses of sevoflurane will be targeted, and steady-state end-tidal (expired) concentrations achieved, while subjects perform a pain and memory cognitive task. At both no-drug baseline and the targeted doses, task and resting-state functional magnetic resonance imaging (MRI) scans will be acquired, and this data will be analyzed subsequently for task-related brain activity(from pain processing and memory formation) and functional connectivity. This work will use a systems neuroscience approach to fill an important knowledge gap about the central effects of inhalational sevoflurane in the context of painful stimulation.

The investigators propose to complete the following 3 Aims, at a sedative dose of Sevoflurane, compared to no-drug baseline, using functional MRI:

Aim 1: Determine how the brain response to acute pain stimulation is modulated by sevoflurane. It is anticipated that sevoflurane will correlate to decreased activation in both somatosensory (thalamus, insula, primary somatosensory/motor) and affective (anterior cingulate) components of the pain processing brain areas.

Aim 2: Determine how memory encoding is modulated by sevoflurane, in the context of periodic painful stimulation. It is anticipated that sevoflurane will correlate to decreased activation in both the explicit memory (hippocampus, parahippocampus) and associative learning (amygdala, anterior cingulate) brain systems.

Aim 3: Determine the neural effects of inhalational sevoflurane on brain connectivity both at rest and during the combined pain and memory task performance. It is anticipated that hypothesize that sevoflurane will cause widespread dose-dependent decreases in long-range functional connectivity between brain areas known to be involved in pain processing and to the default mode network, and that this connectivity will differ between the resting (task-free) and periodic pain states.

Conditions

Anesthesia; Pain; Amnesia

Keywords

functional MRI; sevoflurane; electric nerve stimulation; sedation; functional connectivity

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Sevoflurane+Pain

Single-arm study. All subjects receive sevoflurane and painful electric nerve stimulation, as described in the interventions.

Group Type: EXPERIMENTAL

Sevoflurane

Intervention Type: DRUG

After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration of 0.4% (corresponding to 0.2 Minimum Alveolar Concentration) is reached.

Peripheral Nerve Stimulation

Intervention Type: DEVICE

Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.

Interventions

Sevoflurane

After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration of 0.4% (corresponding to 0.2 Minimum Alveolar Concentration) is reached.

Intervention Type: DRUG

Peripheral Nerve Stimulation

Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.

Intervention Type: DEVICE

Other Intervention Names

Ultane; Electric Nerve Stimulation

Eligibility Criteria

Inclusion Criteria

• Adults, age 18-59, who are native English speakers with at least a high school education
• have normal hearing and memory
• be of normal body-weight
• be generally healthy (free from significant chronic disease)

Exclusion Criteria

• have a valid email address and valid phone number throughout the study
• anticipate ability to participate in all visits required for the phase of the study in which they are enrolled

• being pregnant or attempting to conceive
• having a body mass index (BMI) > 35
• having significant memory impairment or hearing loss
• having sleep apnea
• having chronic pain or frequently taking pain medication (including tramadol)
• having any severe or poorly-controlled medical problem (hypertension, diabetes)
• having neurologic or psychiatric disease, including anxiety, and depression
• having significant cardiac valvular disease or cardiomyopathy
• having a history of abnormal heartbeats (cardiac conduction abnormality or arrhythmia)
• having a history of seizures or convulsions
• having a history of liver disease
• having a history of asthma or other significant pulmonary disease
• having a history of malignant hyperthermia, muscular dystrophy, central core disease, or hyperkalemia
• being claustrophobic
• have metal implants or non-removable metal piercings
• having a history of adverse reaction to anesthetics
• daily alcohol or heavy alcohol use; history of alcohol abuse
• current daily smoker
• regular or recent marijuana use (including prescribed/medical marijuana)
• illicit drug use
• regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids
• current use of selective serotonin reuptake inhibitors (SSRIs), noradrenaline reuptake inhibitors (SNRIs), or monoamine oxidase inhibitors (MAOIs) and some other specific drugs phenytoin, carbamazepine, and rifampin
• history of QT prolongation
• hypersensitivity or allergic reaction to ondansetron (Zofran)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 59 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of General Medical Sciences (NIGMS)

NIH

Sponsor Role: collaborator

Keith M Vogt

OTHER

Sponsor Role: lead

Responsible Party

Keith M Vogt

Associate Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Keith M Vogt, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Keith M Vogt, MD, PhD

Role: CONTACT

Phone: 4126473147

Email: kev18@pitt.edu

Facility Contacts

Keith M Vogt, MD, PhD

Role: primary

Other Identifiers

R35GM146822

Identifier Type: NIH

Identifier Source: secondary_id

View Link

STUDY23070068

Identifier Type: -

Identifier Source: org_study_id